NASDAQ: AUPH
Aurinia Pharmaceuticals Inc Earnings Dates, Reports, Calls

Aurinia Pharmaceuticals earnings were $298.2M for the trailing 12 months ending Mar 31, 2026, with 669% growth year over year. The latest AUPH earnings report on Mar 31, 2026 announced Q1 2026 earnings of $34.4M, down 83.7% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, AUPH reported annual earnings of $287.2M, with 4,893.1% growth.

AUPH past earnings growth

How has AUPH's earnings growth performed historically?

Company
668.97%
Industry
47.1%
Market
85.24%
AUPH's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
AUPH's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Market Performance
AUPH's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

AUPH earnings history

Current Revenue
$298.3M
Current Earnings
$298.2M
Current Profit Margin
100%

AUPH Return on Equity

Current Company
64.5%
Current Industry
-151.3%
Current Market
5.3%
AUPH's Return on Equity (64.5%)... subscribe to Premium to read more.
High Return on Equity Performance

AUPH Return on Assets

Current Company
47.6%
Current Industry
-9.2%
AUPH is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when AUPH announces earnings.

AUPH Return on Capital Employed

Current Company
21.65%
Current Industry
-5.2%
AUPH has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

AUPH vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
AUPH$157.42M$298.21M+668.97%$2.23
TSHA-$127.36M-$129.88MN/A-$0.38
PHVS-$194.72M-$201.95MN/A-$3.41
INBX-$123.57M-$140.06MN/A-$9.04
MBX-$86.24M-$86.61MN/A-$2.16

Aurinia Pharmaceuticals Earnings Reports & History FAQ

What were Aurinia Pharmaceuticals's earnings last quarter?

On AUPH's earnings call on Invalid Date, Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q1 2026 earnings per share (EPS) of $0.26, up 52.94% year over year. Total AUPH earnings for the quarter were $34.36 million. In the same quarter last year, Aurinia Pharmaceuticals's earnings per share (EPS) was $0.17.

If you're new to stock investing, here's how to buy Aurinia Pharmaceuticals stock.

Is Aurinia Pharmaceuticals profitable or losing money?

As of the last Aurinia Pharmaceuticals earnings report, Aurinia Pharmaceuticals is currently profitable. Aurinia Pharmaceuticals's net profit (also called net income) for the twelve months ending Mar 31, 2026 was $298.21 million, a 648.43% increase year over year.

What was AUPH's earnings growth in the past year?

As of Aurinia Pharmaceuticals's earnings date in Invalid Date, Aurinia Pharmaceuticals's earnings has grown 668.97% year over year. This is 621.87 percentage points higher than the US Biotechnology industry earnings growth rate of 47.1%. AUPH earnings in the past year totalled $298.21 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.